PRIMO Post-Market Clinical Follow Up Study

Inclusion Criteria: * Male and female patients aged \>18 * Patients who need a reconstructive procedure and a microsurgical reconstruction is deemed the best option by the plastic, orthopedic or other surgeon in response to a post-oncological, post-traumatic or congenital tissue defect or to treat lymphedema. * Patients who have been selected by the PI at the Clinical Center as appropriate candidates for treatment with Symani System in accordance with the IFU. * Subjects who fit the criteria to perform surgery requiring reconstructions using free flaps, replantation, lymphatic reconstructions. * Subjects who agree to have the surgery and the anaesthesia. * Subjects who voluntarily decide to participate in this study with the surgery performed with the aid of the Symani System and sign the Informed Consent Form. Exclusion Criteria: * Subjects who have bleeding or coagulation disorders in the past or present. * Any criteria that preclude prolonged anesthesia. * History of anaphylaxis or severe complicated allergy symptoms. * Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders or previous mental disorders that may significantly affect the data collection or the ability to comply with the protocol. * Evidence or history of autoimmune disease or compromised immune system. * Participation in another clinical trial within 4 weeks prior to participation in the study. * Subjects belonging to vulnerable populations or ineligible to participate for other reasons by the PI at a Clinical Center. * Subjects with pacemaker